Physician profile
Shashi Lall
NPI 1730166448
$903.61
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $62.18 · 2021: $208 · 2022: $38.06 · 2023: $133 · 2024: $18.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $151.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $133.09 | 2023 | Octrode |
| Horizon Therapeutics Plc | $108.64 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $99.47 | 2021 | |
| Janssen Pharmaceuticals, INC | $89.64 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $75.31 | 2019-2020 | |
| Pfizer INC. | $68.72 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $54.06 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $45.48 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $38.76 | 2019 | |
| Lilly USA, LLC | $37.90 | 2019 | |
| Glaxosmithkline, LLC. | $37.46 | 2019 | |
| Amarin Pharma, INC. | $34.92 | 2019 | |
| Amgen INC. | $32.55 | 2019-2022 | |
| Ibsa Pharma INC. | $18.81 | 2024 | Licart, Tirosint |
| Circassia INC. | $14.65 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $14.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shashi Lall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.